July 11, 2019

FDA to Review Isatuximab as a Potential Treatment for R/R Multiple Myeloma

PARIS – July 10, 2019 – The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for isatuximab for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). The target action date for the FDA decision is April 30, 2020. Isatuximab is an investigational monoclonal antibody that targets a specific […]

Read more